Atrasentan in patients with IgA nephropathy (ALIGN): final 2&#xb7;5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Further Publications Urology

Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial

Lancet

Heerspink HJL, Cardona JF, Jolly S, Pergola PE, de Sousa-Amorim E, Eriksson AL, Fredholm M, Gasparyan SB, Guzman NJ, Hartleib-Geschwindner J, Jiang Y, Leonsson-Zachrisson M, Mark PB, MIRO-CKD study investigators

doi: 10.1016/S0140-6736(25)02014-8

Further Publications Urology

Sibeprenlimab in IgA Nephropathy - Final Phase 3 Trial Analysis

N Engl J Med

Rizk DV, Barratt J, Suzuki Y, Zhang H, Wong MG, Liew A, Lafayette R, Tesař V, Trimarchi H, Carroll K, Roberts ISD, Jha V, Quevedo A, Han SH, Yahya R, Cheung CK, Ramachandran R, Walsh M, Chacko B, Praga M, Chen JB, Suassuna J, Xia J, Shah L, Perkovic V, VISIONARY Trial Investigators Group

doi: 10.1056/NEJMoa2609127

Pregnancy and ChildbirthEndometriosis

A double-blind multi-centre randomised placebo-controlled trial of doxycycline in women with recurrent miscarriage and chronic endometritis defined by CD138 positive stromal cells

Hum Reprod

Odendaal J, Black N, Fishwick K, Thornton J, Makwana K, Ewington L, Larsen K, Hawkes A, Leeson C, Fisher J, Lall R, Guck J, Coomarasamy A, Granne I, Underwood M, Bouliotis G, Quenby S

doi: 10.1093/humrep/deag133

Erectile and Sexual Functions and Dysfunctions

A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials

J Sex Med

Salonia A, Bettocchi C, Burnett A, Corona G, Fode M, Hassan T, Minhas S, Mulhall JP, Sadeghi-Nejad H, Vignesh SO, Wang R, Jannini EA

doi: 10.1093/jsxmed/qdag176

Urinary Tract Infections (UTI)

Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial

Lancet

Takahashi S, Tateda K, Yanagihara K, Huang H, Doi Y, Yasuda M, Matsumoto K, Sumiya M, Takaya R, Suwada K, Kamiyabu S, Sasagawa Y, Minamida T, Kato S, Kondo K, Naruse T, Mikamo H

doi: 10.1016/S0140-6736(26)00596-9

Further Publications Urology

Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy

N Engl J Med

Barratt J, Zhang H, Han SH, Suzuki Y, Tumlin J, Chacko B, Noronha IL, Madan A, Duivenvoorden R, Azzi JR, Nester C, Dong C, Ahluwalia N, Li J, Bozic C, Egbuna O, Wong MG, Lafayette R, RAINIER AIS-D08 Trial Group

doi: 10.1056/NEJMoa2608682

Further Publications Urology

Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial

Eur Urol

Tikkinen KAO, Marcucci M, Halme ALE, Ofori SN, Borges FK, Kanstrup CTB, Park LJ, Tondroanamag F, Kilpeläinen TP, Tornberg SV, Painter TW, Conen D, Lomivorotov V, Sessler DI, Chan MTV, Martinez-Zapata MJ, Wang CY, Xavier DB, Wang MK, Szczeklik W, Leslie K, Lavallee LT, Breau RH, Balasubramanian K, Devereaux PJ

doi: 10.1016/j.eururo.2026.03.019

Further Publications Urology

Patient-reported outcome measures of percutaneous nephrostomy vs JJ stent in obstructive urolithiasis: results of the STent Or NEphrostomy (STONE) randomised controlled trial

BJU Int

Schuil HW, Hendriks N, Duijnhoven RG, Oskam BCH, Arends TJH, Duijvesz D, Horsch AD, van der Heij B, Tjiam IM, van Overhagen H, Lamers ABGN, van Delden OM, Scheepens WA, Drossaerts JMA, d'Ancona FCH, Boering S, van Uhm JIM, van der Meer RW, van Roijen JH, de Kiefte M, Hendrikx AJM, Weltings S, Pelger RCM, Beerlage HP, Schout BMA, Kamphuis GM

doi: 10.1111/bju.70249

Benign Prostatic Hyperplasia (BPH)

The role of 5-alpha reductase inhibitors in transurethral resection of the prostate: a meta-analysis of randomised controlled trials

BJU Int

Hehir CM, Calpin GG, Cullivan O, Daly GR, Dowling GP, Davis NF

doi: 10.1111/bju.70117

Gynecology · Urology

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Related content

Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial

Sibeprenlimab in IgA Nephropathy - Final Phase 3 Trial Analysis

A double-blind multi-centre randomised placebo-controlled trial of doxycycline in women with recurrent miscarriage and chronic endometritis defined by CD138 positive stromal cells

A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials

Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial

Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy

Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial

Patient-reported outcome measures of percutaneous nephrostomy vs JJ stent in obstructive urolithiasis: results of the STent Or NEphrostomy (STONE) randomised controlled trial

The role of 5-alpha reductase inhibitors in transurethral resection of the prostate: a meta-analysis of randomised controlled trials